Placebo News and Research

RSS

Thanks to Reddit, a new diagnosis is bubbling up across the nation

In a video posted to Reddit this summer, Lucie Rosenthal's face starts focused and uncertain, looking intently into the camera, before it happens.

6 Sep 2024

Mindfulness meditation reduces pain through distinct brain mechanisms

Pain is a complex, multifaceted experience shaped by various factors beyond physical sensation, such as a person's mindset and their expectations of pain.

5 Sep 2024

Aficamten improves exercise tolerance in patients with HOCM

Exercise intolerance is often severe among patients with cardiovascular disease and can impose significant limitations on their physical abilities and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease in which the heart muscle becomes thickened leading to reduced blood flow out of the heart.

5 Sep 2024

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.

5 Sep 2024

Study aims to find new ways of alleviating the long-term effects of COVID-19

An innovative study for the treatment of post-COVID syndrome (PCS) is starting under the direction of Frankfurt University Hospital’s Department of Infectious Diseases.

4 Sep 2024

Anti-coagulant therapy fails to improve stroke outcomes in major study

Stroke patients who survive a blood clot in the brain's blood vessels are prone to developing new blockages during their recovery periods, even if they receive vessel-clearing interventions.

4 Sep 2024

Semaglutide does not increase risk of depression or suicidal thoughts

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine.

4 Sep 2024

Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

Intensive LDL-C lowering with alirocumab significantly reduces high-risk coronary plaque burden, transforming unstable plaques into more stable phenotypes. This lesion-level analysis underscores the enhanced efficacy compared to vessel-level approaches.

4 Sep 2024

Study reassures patients about semaglutide safety

4 Sep 2024

Major trial to test multiple drugs for progressive supranuclear palsy

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start.

3 Sep 2024

Mineralocorticoid receptor antagonists reduce risk of cardiovascular events in patients with heart failure

MRAs significantly lower the risk of cardiovascular death and HF hospitalization in heart failure patients.

3 Sep 2024

Matcha green tea enhances cognition and sleep in older adults

Regular matcha green tea consumption may improve emotional perception and sleep quality in older adults with cognitive decline, though it shows no significant effect on broader cognitive functions.

2 Sep 2024

$FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction$

FINEARTS-HF trial shows finerenone benefits for heart failure with preserved ejection fraction

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

$Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions$

Mineralocorticoid receptor antagonists benefit heart failure patients across ejection fractions

Mineralocorticoid receptor antagonists (MRAs) reduced the risk of cardiovascular death or heart failure (HF) hospitalization in patients with HF and reduced ejection fraction (HFrEF) and also in those with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

Catheter ablation proven effective for atrial fibrillation in new study

A catheter ablation procedure widely used to treat the most common heart rhythm disorder significantly reduces the burden of atrial fibrillation (AF) and results in clinically important improvements in symptoms and quality of life compared with a sham (placebo) procedure, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug - 2 Sept).

2 Sep 2024

$Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction$

Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial led by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.

2 Sep 2024

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds.

30 Aug 2024